Cystic fibrosis 2019: Year in review.
Paediatr Respir Rev
; 35: 95-98, 2020 Sep.
Article
em En
| MEDLINE
| ID: mdl-32359945
ABSTRACT
The evidence base for modulator therapies in cystic fibrosis (CF) has continued to expand, and it is likely that up to 90% of people with CF could benefit. Worldwide there are however marked inequalities of access to basic CF care and modulator therapies. For infants and young children there is now an evidence base for inhaled hypertonic saline. There is increasing evidence that structural lung disease in CF is not due purely to infection and that mucus retention and inflammation are also key, and further evidence of the value of azithromycin in those chronically infected with Pseudomonas aeruginosa. Finally, exercise is good for you, but airway clearance is better for mucus clearance.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Solução Salina Hipertônica
/
Exercício Físico
/
Modalidades de Fisioterapia
/
Fibrose Cística
/
Agonistas dos Canais de Cloreto
/
Antibacterianos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article